Department of Surgery, Osaka National Hospital. 2-1-14, Hoenzaka, Chuo-ku, Osaka 540-0006, Japan.
Anticancer Res. 2012 Feb;32(2):665-70.
BACKGROUND/AIM: The optimal treatment of liver metastases from gastric cancer (LMGC) remains uncertain. We retrospectively compared surgical treatment with chemotherapy alone and identified prognostic determinants.
We reviewed the records of 50 consecutive patients with LMGC: 25 patients with gastrectomy plus hepatic resection (group A), 13 patients with palliative gastrectomy (group B), and 12 patients with chemotherapy alone (group C). We compared the overall survival among these three groups, and assessed prognostic factors.
Median survival time in groups A, B, and C was 33.4, 10.5, and 8.7 months, respectively. Univariate analysis found T stage, number of liver metastases, and treatment group to be significant prognostic factors. In the multivariate analysis, T stage was shown to be an independent prognostic determinant, while gastrectomy plus hepatic resection was of marginal significance compared with chemotherapy alone.
T Stage was a significant prognostic determinant, and gastrectomy plus hepatic resection could be a promising treatment for patients with LMGC.
背景/目的：胃癌肝转移（LMGC）的最佳治疗方法仍不确定。我们回顾性比较了单纯手术治疗与化疗，并确定了预后决定因素。
我们回顾了 50 例连续 LMGC 患者的记录：25 例接受胃切除术加肝切除术（A 组），13 例接受姑息性胃切除术（B 组），12 例接受单纯化疗（C 组）。我们比较了这三组的总生存率，并评估了预后因素。
A、B 和 C 组的中位生存时间分别为 33.4、10.5 和 8.7 个月。单因素分析发现 T 分期、肝转移数量和治疗组是显著的预后因素。多因素分析显示 T 分期是独立的预后决定因素，而胃切除术加肝切除术与单纯化疗相比具有边缘意义。
T 分期是一个显著的预后决定因素，胃切除术加肝切除术可能是 LMGC 患者有希望的治疗方法。
